Nektar Therapeutics(NKTR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NKTR Nektar Therapeutics

Post-Mkt 12-11 17:34:37 EST

51.12

-6.62

-11.47%

盘后51.51

+0.39+0.76%

17:32 EST

High57.90	Low51.04	Vol909.76K
Open57.33	D1 Closing57.74	Amplitude11.88%
Mkt Cap1.04B	Tradable Cap899.42M	Total Shares20.34M
T/O48.93M	T/O Rate5.17%	Tradable Shares17.59M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NKTR","market":"US","secType":"STK","nameCN":"Nektar Therapeutics","latestPrice":51.12,"timestamp":1765486800000,"preClose":57.74,"halted":0,"volume":909756,"hourTrading":{"tag":"盘后","latestPrice":51.5091,"preClose":51.12,"latestTime":"17:32 EST","volume":6936,"amount":355197.92152800004,"timestamp":1765492372272},"delay":0,"floatShares":17594200,"shares":20341589,"eps":-7.899717,"marketStatus":"Post-Mkt","change":-6.62,"latestTime":"12-11 17:34:37 EST","open":57.33,"high":57.9,"low":51.04,"amount":48926079.970308,"amplitude":0.118808,"askPrice":51.51,"askSize":100,"bidPrice":51.26,"bidSize":15,"shortable":0,"etf":0,"ttmEps":-7.899717,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1765501200000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":57.74,"preHourTrading":{"tag":"盘前","latestPrice":57.04,"preClose":57.74,"latestTime":"09:28 EST","volume":6490,"amount":376572.9044,"timestamp":1765463298746},"postHourTrading":{"tag":"盘后","latestPrice":51.5091,"preClose":51.12,"latestTime":"17:32 EST","volume":6936,"amount":355197.92152800004,"timestamp":1765492372272},"volumeRatio":1.986053,"impliedVol":1.4062,"impliedVolPercentile":0.6546},"requestUrl":"/m/hq/s/NKTR","defaultTab":"news","newsList":[{"id":"2589843528","title":"Nektar Therapeutics Grants Stock Options to New Employees Under 2025 Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2589843528","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589843528?lang=en_us&edition=fundamental","pubTime":"2025-12-06 07:00","pubTimestamp":1764975611,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics has granted non-qualified stock options to two newly hired employees under its 2025 Inducement Plan. One employee received options to purchase 7,260 shares at an exercise price of $60.35 per share, based on the closing price on November 25, 2025. The other employee received options for 11,050 shares at an exercise price of $57.69 per share, the closing price on December 4, 2025. The options have an eight-year term and will vest over four years, with a quarter of the shares vesting after one year and the remainder vesting monthly over the next three years, contingent on continued employment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nektar Therapeutics published the original content used to generate this news br","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nNDLbTw9G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"2589184358","title":"Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2589184358","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589184358?lang=en_us&edition=fundamental","pubTime":"2025-12-06 07:00","pubTimestamp":1764975600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nTUA2MWWVY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NKTR"],"gpt_icon":0},{"id":"2586262856","title":"Nektar Therapeutics Is Maintained at Buy by Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2586262856","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586262856?lang=en_us&edition=fundamental","pubTime":"2025-11-27 02:42","pubTimestamp":1764182520,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NKTR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 26, 2025 13:42 ET (18:42 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR"],"gpt_icon":0},{"id":"2586825085","title":"Nektar price target raised to $121 from $99 at Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2586825085","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586825085?lang=en_us&edition=fundamental","pubTime":"2025-11-26 21:35","pubTimestamp":1764164137,"startTime":"0","endTime":"0","summary":"Jefferies raised the firm’s price target on Nektar (NKTR) to $121 from $99 and keeps a Buy rating on the shares. With “relatively low expectations”...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nektar-price-target-raised-to-121-from-99-at-jefferies-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nektar-price-target-raised-to-121-from-99-at-jefferies-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"2586285794","title":"Nektar Therapeutics President and CEO Howard W. Robin Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2586285794","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586285794?lang=en_us&edition=fundamental","pubTime":"2025-11-26 09:29","pubTimestamp":1764120554,"startTime":"0","endTime":"0","summary":"Howard W. Robin, President & CEO of Nektar Therapeutics, has reported a disposal of common shares of Nektar Therapeutics. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nektar Therapeutics published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 25, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nNDL1fmLQ0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Nektar Therapeutics President and CEO Howard W. Robin Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"2586472904","title":"How Investors May Respond To Nektar Therapeutics (NKTR) Clinical Progress and Leadership Transition","url":"https://stock-news.laohu8.com/highlight/detail?id=2586472904","media":"Simply Wall St.","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586472904?lang=en_us&edition=fundamental","pubTime":"2025-11-25 22:33","pubTimestamp":1764081190,"startTime":"0","endTime":"0","summary":"Earlier this month, Nektar Therapeutics announced favorable new clinical data for its Phase 2b REZOLVE-AD study in atopic dermatitis and outlined an executive leadership transition, with Elizabeth Zhang set to become Chief Legal Officer at the end of December 2025.\nThe company’s strengthened clinical pipeline and upcoming legal leadership change highlight its ongoing efforts to balance innovation with organizational continuity.\nWe’ll explore how encouraging trial results for REZPEG could...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/how-investors-may-respond-to-nektar-therapeutics-nktr-clinic","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/how-investors-may-respond-to-nektar-therapeutics-nktr-clinic","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ISBC","BK4097","BK4007","NKTR","BK4211","LU2065732104.USD","PRGS"],"gpt_icon":0},{"id":"2585012610","title":"Nektar Therapeutics Announces Chief Legal Officer Departure","url":"https://stock-news.laohu8.com/highlight/detail?id=2585012610","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585012610?lang=en_us&edition=fundamental","pubTime":"2025-11-22 05:34","pubTimestamp":1763760861,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics ( ($NKTR) ) has issued an announcement. On November 21, 2025, Nektar Therapeutics announced the departure of Mark A. Wilson as ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nektar-therapeutics-announces-chief-legal-officer-departure?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nektar-therapeutics-announces-chief-legal-officer-departure?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"2585512575","title":"Nektar Therapeutics Names Elizabeth Zhang as Chief Legal Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2585512575","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585512575?lang=en_us&edition=fundamental","pubTime":"2025-11-22 05:06","pubTimestamp":1763759216,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics announced that Mark A. Wilson will step down as Chief Legal Officer effective December 31, 2025. Elizabeth Zhang, currently Vice President, Legal and Corporate Counsel, will assume his responsibilities. Zhang has been with Nektar since 2021 and previously worked at Cravath, Swaine & Moore LLP and Gibson, Dunn & Crutcher LLP.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nektar Therapeutics published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 21, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nNDL5BnGnD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"2584929935","title":"Nektar Therapeutics Q3 EPS USD -1.87","url":"https://stock-news.laohu8.com/highlight/detail?id=2584929935","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584929935?lang=en_us&edition=fundamental","pubTime":"2025-11-20 00:58","pubTimestamp":1763571538,"startTime":"0","endTime":"0","summary":"Nov 06 (Reuters) - Nektar Therapeutics Q3 income from operations USD -31.672 million.:  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 06-NOV-202521:13:38.513 GMT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD84X96c:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NKTR"],"gpt_icon":0},{"id":"2584114946","title":"Nektar Therapeutics (NKTR): Assessing Valuation After $110 Million Equity Offering and New Shelf Registrations","url":"https://stock-news.laohu8.com/highlight/detail?id=2584114946","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584114946?lang=en_us&edition=fundamental","pubTime":"2025-11-17 10:20","pubTimestamp":1763346051,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics (NKTR) announced a $110 million follow-on equity offering, along with new shelf registrations for multiple securities. Moves like this can reshape the company's capital position and influence how investors gauge its future outlook.\nSee our latest analysis for Nektar Therapeutics.\nThis fresh fundraising push comes shortly after Nektar Therapeutics’ recent FDA fast track designations, new product data, and a third-quarter earnings report showing narrower year-over-year...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/nektar-therapeutics-nktr-assessing-valuation-after-110-milli","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/nektar-therapeutics-nktr-assessing-valuation-after-110-milli","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NKTR","BK4588","BK4585","BK4007","EQR","BK4215"],"gpt_icon":0},{"id":"2583203656","title":"Nektar Therapeutics: Buy Rating Driven by Promising REZPEG Data and Favorable Safety Profile in Alopecia Areata Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2583203656","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583203656?lang=en_us&edition=fundamental","pubTime":"2025-11-16 01:25","pubTimestamp":1763227550,"startTime":"0","endTime":"0","summary":"Analyst Julian Harrison of BTIG maintained a Buy rating on Nektar Therapeutics, retaining the price target of $100.00. Julian Harrison has given hi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/nektar-therapeutics-buy-rating-driven-by-promising-rezpeg-data-and-favorable-safety-profile-in-alopecia-areata-treatment-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/nektar-therapeutics-buy-rating-driven-by-promising-rezpeg-data-and-favorable-safety-profile-in-alopecia-areata-treatment-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NKTR"],"gpt_icon":0},{"id":"2583589109","title":"Nektar Therapeutics - May Sell Shares Worth up to $110 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2583589109","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583589109?lang=en_us&edition=fundamental","pubTime":"2025-11-13 06:29","pubTimestamp":1762986557,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nFWN3WO1FZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"2583589105","title":"Nektar Therapeutics - Enters Equity Distribution Agreement With Piper Sandler & Btig - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2583589105","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583589105?lang=en_us&edition=fundamental","pubTime":"2025-11-13 06:29","pubTimestamp":1762986557,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nFWN3WO1FZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"2583583932","title":"Nektar files automatic mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2583583932","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583583932?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:10","pubTimestamp":1762981839,"startTime":"0","endTime":"0","summary":"16:09 EST Nektar (NKTR) files automatic mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving breakin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nektar-files-automatic-mixed-securities-shelf-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nektar-files-automatic-mixed-securities-shelf-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","NKTR"],"gpt_icon":0},{"id":"2583881635","title":"Nektar Therapeutics Files for Mixed Shelf Offering, Size Not Disclosed  - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2583881635","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583881635?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:09","pubTimestamp":1762981750,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nFWN3WO1FK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"2582651593","title":"H.C. Wainwright Reaffirms Their Buy Rating on Nektar Therapeutics (NKTR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582651593","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582651593?lang=en_us&edition=fundamental","pubTime":"2025-11-11 19:56","pubTimestamp":1762862209,"startTime":"0","endTime":"0","summary":"In a report released today, Arthur He CFA from H.C. Wainwright reiterated a Buy rating on Nektar Therapeutics, with a price target of $120.00. He C...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-reaffirms-their-buy-rating-on-nektar-therapeutics-nktr-blurbs-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-reaffirms-their-buy-rating-on-nektar-therapeutics-nktr-blurbs-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NKTR"],"gpt_icon":0},{"id":"2582808102","title":"PharmaEssentia Appoints Dr. Barry Flannelly as Independent Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2582808102","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582808102?lang=en_us&edition=fundamental","pubTime":"2025-11-10 23:32","pubTimestamp":1762788744,"startTime":"0","endTime":"0","summary":"PharmaEssentia Corporation has appointed Dr. Barry Flannelly as Independent Director of its U.S. subsidiary. Dr. Flannelly brings over 25 years of biopharma leadership experience, including roles at Incyte Corporation, Sanofi, Novartis, Abraxis Oncology, Onyx Pharmaceuticals, and Nektar Therapeutics. He is also a current board member of Protara Therapeutics.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PharmaEssentia Corporation published the original content used to generate this news brief via Business Wire  on November 10, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL7KH1PX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1057294990.SGD","INCY","TARA","BK4588","IE0002141913.USD","LU2112291526.USD","LU2089984988.USD","IE00B4R5TH58.HKD","LU1571399168.USD","BK4533","BK4550","BK4139","BK4581","LU0122379950.USD","LU0289739699.SGD","BK4566","LU1061106388.HKD","SG9999001440.SGD","NKTR","BK4599","BK4534","BK4532","IE00BJT1NW94.SGD","LU1023059063.AUD","LU0109394709.USD","LU2468319806.SGD","IE00B2B36J28.USD","LU0889565916.HKD","LU0868494617.USD","LU0058720904.USD","IE00BFTCPJ56.SGD","LU2242652126.USD","BK4007","LU1983299246.USD","IE0009355771.USD","LU0320765992.SGD","IE00BJJMRZ35.SGD","LU2242646821.SGD","BK4585","AMGN"],"gpt_icon":0},{"id":"2582066820","title":"Nektar Therapeutics Reports Positive Phase 2b Results for Rezpegaldesleukin in Atopic Dermatitis and Asthma","url":"https://stock-news.laohu8.com/highlight/detail?id=2582066820","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582066820?lang=en_us&edition=fundamental","pubTime":"2025-11-10 19:31","pubTimestamp":1762774318,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics has announced new data from the ongoing Phase 2b REZOLVE-AD clinical study evaluating rezpegaldesleukin, a first-in-class IL-2 pathway agonist and regulatory T-cell biologic, in patients with moderate-to-severe atopic dermatitis. The results were presented on November 8, 2025, in a late-breaking oral abstract session at the American College of Allergy, Asthma & Immunology  2025 Annual Scientific Meeting. The study demonstrated statistically significant and clinically meaningful improvements in key efficacy endpoints, including mean ACQ-5 scores at week 16 versus placebo in patients with atopic dermatitis and a history of asthma. Additional improvements were observed across major endpoints such as EASI-75, EASI-90, vIGA-AD, and NRS-Itch at Week 16, with continued benefits noted from Week 16 to 24. Data from the long-term maintenance portion of the study, with 52 weeks of treatment, are expected in the first quarter of 2026. Nektar also indicated that top-line Phase 2","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL3ZJxbV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"1128888665","title":"Stock Track | Nektar Therapeutics Soars 5.43% Pre-market, Extending Recent Rally Amid Bullish Analyst Forecasts","url":"https://stock-news.laohu8.com/highlight/detail?id=1128888665","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128888665?lang=en_us&edition=fundamental","pubTime":"2025-11-10 19:08","pubTimestamp":1762772905,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics (NKTR) shares surged 5.43% in pre-market trading on Monday, continuing the stock's impressive rally over recent months. This latest jump comes as investors anticipate potential...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["NKTR"],"gpt_icon":0},{"id":"1147713503","title":"Stock Track | Nektar Therapeutics Soars 5.43% in Pre-market Trading Amid Bullish Sentiment and Valuation Debate","url":"https://stock-news.laohu8.com/highlight/detail?id=1147713503","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147713503?lang=en_us&edition=fundamental","pubTime":"2025-11-10 19:08","pubTimestamp":1762772903,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics (NKTR) stock jumped 5.43% in pre-market trading on Monday, continuing its impressive rally that has seen shares nearly triple in value over the past three months. The biotech...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["NKTR"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.nektar.com","stockEarnings":[{"period":"1week","weight":0.0107},{"period":"1month","weight":-0.004},{"period":"3month","weight":0.2233},{"period":"6month","weight":5.7218},{"period":"1year","weight":2.7739},{"period":"ytd","weight":3.1391}],"compareEarnings":[{"period":"1week","weight":0.0054},{"period":"1month","weight":0.009},{"period":"3month","weight":0.0455},{"period":"6month","weight":0.1517},{"period":"1year","weight":0.1406},{"period":"ytd","weight":0.1732}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc.  The company was incorporated in 1990 and is headquartered in San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.548387,"avgChangeRate":0.042868},{"month":2,"riseRate":0.516129,"avgChangeRate":0.003089},{"month":3,"riseRate":0.387097,"avgChangeRate":-0.002052},{"month":4,"riseRate":0.451613,"avgChangeRate":0.01158},{"month":5,"riseRate":0.354839,"avgChangeRate":0.003107},{"month":6,"riseRate":0.40625,"avgChangeRate":0.024924},{"month":7,"riseRate":0.4375,"avgChangeRate":-0.019557},{"month":8,"riseRate":0.46875,"avgChangeRate":0.044887},{"month":9,"riseRate":0.5,"avgChangeRate":0.042479},{"month":10,"riseRate":0.375,"avgChangeRate":-0.023288},{"month":11,"riseRate":0.6875,"avgChangeRate":0.087128},{"month":12,"riseRate":0.59375,"avgChangeRate":0.022951}],"exchange":"NASDAQ","name":"Nektar Therapeutics","nameEN":"Nektar Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Nektar Therapeutics(NKTR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Nektar Therapeutics(NKTR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Nektar Therapeutics,NKTR,Nektar Therapeutics股票,Nektar Therapeutics股票老虎,Nektar Therapeutics股票老虎国际,Nektar Therapeutics行情,Nektar Therapeutics股票行情,Nektar Therapeutics股价,Nektar Therapeutics股市,Nektar Therapeutics股票价格,Nektar Therapeutics股票交易,Nektar Therapeutics股票购买,Nektar Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Nektar Therapeutics(NKTR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Nektar Therapeutics(NKTR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction